Lexicon announces data from STOA-INS CGM Phase 3 trial

Lexicon Pharmaceuticals announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated that once-daily dosing of sotagliflozin 400 mg improved time-in-range, TIR, and several continuous glucose monitoring, CGM, parameters, including glucose variability, in insulin-treated type 2 diabetes, T2D, patients. Researchers also observed positive trends with the once-daily dose of 200 mg. Study findings will be presented September 12th at the 60th Annual Meeting of the European Association for the Study of Diabetes, EASD, in Madrid, Spain and online. The objective of the SOTA-INS CGM study was to evaluate the effect of sotagliflozin on TIR as assessed by CGM in people with T2D. The primary sub-study endpoint was mean change in percentage of time spent within TIR over 24 hours for sotagliflozin 400 mg versus placebo.